Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 10, 2009

Life Technologies Offers Next-Gen Platform to University of Cambridge’s Sequencing Hub

  • Life Technologies is providing three SOLiD™ 3 Plus Systems to the European research and clinical communities through the Eastern Sequence and Informatics Hub at Addenbrooke’s Hospital in Cambridge. The technology will be leveraged in diseases such as cancer, diabetes, and neurological disorders to advance targeted medical resequencing and whole-transcriptome analysis research studies.

    The hub was established with funding from the Medical Research Council and from the University of Cambridge’s Clinical School and NIHR Biomedical Research Centre to accelerate the use of genetic information to help identify new therapies, diagnostics, and preventive strategies.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »